Vor Biopharma Inc reports results for the quarter ended in September - Earnings Summary

Vor Biopharma

10/11/2022 23:37

* Vor Biopharma Inc  VOR.OQ  reported a quarterly adjusted
loss
of 63 cents​​ per share for the quarter ended in September. The
mean expectation of eight analysts for the quarter was for a
loss of 61 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Vor Biopharma Inc's reported EPS for the quarter was a
loss
of 63 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Vor Biopharma Inc shares had risen by 2.5% this
quarter and
lost 64.9% so far this year.
    * The company reported a quarterly loss of $23.79 million.
    * Wall Street's median 12-month price target for Vor
Biopharma Inc
is $20.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 11:36 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.61          -0.63          Missed
 Jun. 30 2022      -0.66          -0.58          Beat
 Mar. 31 2022      -0.51          -0.61          Missed
 Dec. 31 2021      -0.57          -0.48          Beat